Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer in the absence of visceral crisis (1). The gene discussed is NR4A1; the disease is breast cancer.